(Q42165788)

17 October 2017

title

A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. (English)

1 reference

17 October 2017

1 reference

1 reference

13

1 reference

17 October 2017

3

Yilmaz Cakaloglu

1 reference

17 October 2017

1

Vincent Rijckborst

1 reference

17 October 2017

Martijn J ter Borg

2

0 references

Krzysztof Simon

object named as

Krzysztof Simon

7

0 references

author name string

Peter Ferenci

4

1 reference

17 October 2017

Fehmi Tabak

5

1 reference

17 October 2017

Meral Akdogan

6

1 reference

17 October 2017

Maria Raptopoulou-Gigi

8

1 reference

17 October 2017

Necati Ormeci

9

1 reference

17 October 2017

Pieter E Zondervan

10

1 reference

17 October 2017

Elke Verhey

11

1 reference

17 October 2017

Anneke J van Vuuren

12

1 reference

17 October 2017

Harry L A Janssen

14

1 reference

17 October 2017

PARC Study Group

15

1 reference

17 October 2017

language of work or name

English

0 references

publication date

11 May 2010

1 reference

The American Journal of Gastroenterology

17 October 2017

published in

1 reference

17 October 2017

volume

105

1 reference

17 October 2017

issue

8

1 reference

17 October 2017

page(s)

1762-1769

1 reference

Hepatitis B Virus Infection

17 October 2017

uses

randomized experiment

0 references

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2010.186

https://api.fatcat.wiki/v0/release/barktdezkzcnddk7jfw45bwmf4

21 January 2018

Identifiers

1 reference

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_barktdezkzcnddk7jfw45bwmf4

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/barktdezkzcnddk7jfw45bwmf4

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/barktdezkzcnddk7jfw45bwmf4

1 reference